Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227583 | 1.00 | MGLL (0.48) | MGLLHSD11B1POLBHTR2ASMN1; SMN2 | |
| SCHEMBL227582 | 1.00 | MGLL (0.48) | MGLLHSD11B1POLBHTR2ASMN1; SMN2 | |
| SCHEMBL2533784 | 1.00 | MGLL (0.48) | MGLLHSD11B1POLBHTR2ASMN1; SMN2 | |
| SCHEMBL228270 | 0.94 | MGLL (0.47) | MGLLHSD11B1POLBHTR2ASMN1; SMN2 | |
| SCHEMBL228271 | 0.94 | MGLL (0.47) | MGLLHSD11B1POLBHTR2ASMN1; SMN2 | |
| SCHEMBL229208 | 0.82 | SMN1; SMN2 (0.56) | MGLLHSD11B1POLBHTR2ASMN1; SMN2 | |
| SCHEMBL229207 | 0.82 | SMN1; SMN2 (0.56) | MGLLHSD11B1POLBHTR2ASMN1; SMN2 | |
| SCHEMBL228722 | 0.81 | MGLL (0.54) | MGLLHSD11B1POLBHTR2ASMN1; SMN2 | |
| SCHEMBL228723 | 0.81 | MGLL (0.54) | MGLLHSD11B1POLBHTR2ASMN1; SMN2 | |
| SCHEMBL5047556 | 0.80 | HTR2C (0.48) | HTR2ASMN1; SMN2LMNAHTTHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039490-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HTR2A, HTR3A, HTR2C | MGLL 4338/4885HSD11B1 4592/4885POLB 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.